We measured the Candida metabolite D-arabinitoi and its enantiomer i.-arabinitol in 42 serum samples from 33 patients with sarcoidosis and compared the results with those from 27 healthy adults and 4 patients with candidiasis. The D-and L,-arabinitol concentrations and the i)-and î.-arabinitoi/creatinine ratios did not differ significantly in the sarcoidosis patients and the controls; the i)-arabinitol concentrations and the D-arabinitol/ creatinine ratios were much higher in the patients with candidiasis. Among the patients with sarcoidosis, the D-and L-arabinitol levels in the steroid recipients did not differ significantly from those in patients not receiving steroids. Higher D-arabinitoi/creatinine ratios were associated with roentgenographic evidence of pulmonary fibrosis and low forced vital capacities, but not with disease activity as determined by the proportion of lymphocytes to total nucleated cells in bronchoalveolar lavage fluid or the CD4/CD8 ratio in bronchoalveolar lymphocytes. We conclude that neither sarcoidosis nor corticosteroid treatment is associated with high levels of »)-arabinitol in serum.
D-Arabinitol is a major metabolic product of the medically important Catuldidl species, and animals and humans with invasive candidiasis have more arabinitol in their body fluids and tissues than uninfected controls (3, 4, 7, 9, 12, 13, 15, 18, 20, 21) . It has thus been proposed that D-arabinitoi is a quantitative diagnostic marker for candidiasis. The usefulness of this diagnostic approach clearly depends on the specificity of elevated levels of D-arabinitol in body fluid for candidiasis. Many groups have reported that renal failure causes high levels of arabinitol in serum (4, 7. 9-13, 15, [18] [19] [20] [21] . However, this does not limit the usefulness of arabinitol as a diagnostic marker because the effects of renal failure are predictable and can be corrected for by calculating the arabinitol/creatinine ratios (7, 19) .
Two other conditions have also been associated with high levels of arabinitol in serum. Karam et al. reported high levels of arabinitol in serum from patients with sarcoidosis (8) , and de Repentigny et al. reported high arabinitol levels in serum from uninfected rabbits (5) and humans (6) receiving corticosteroids. We studied an additional group of steroidtreated and untreated sarcoidosis patients because of concerns about the methods used in the earlier studies and because a method for quantifying the fungal metabolite D-arabinitol enantioselectively in human serum is now available (21 (19, 21) .
The serum arabinitoi results in the patients with sarcoidosis were compared with those obtained previously from 27 healthy adults and 4 patients with Cunldid(l fungemia or histologically proven invasive candidiasis (21) . Means were compared by using the Student t test, and linear regression analyses were by least-squares methods.
RESULTS
Characteristics of the patients studied. All 33 sarcoidosis patients had typical clinical and laboratory features. and Nineteen serum samples were from patients who were receiving 5 to 40 mg of prednisone per day, and 23 serum samples were from patients who were not receiving steroids.
Serum arabinitol results. The serum D-and L-arabinitol concentrations and the D-and L-arabinitol/creatinine ratios in the 42 serum samples from the patients with sarcoidosis, the 27 healthy adults, and the 4 patients with candidiasis are summarized in Table 1 . There were no significant differences between the values for the sarcoidosis patients and those for the healthy adults; the D-arabinitol concentrations and the D-arabinitol/creatinine ratios were much higher in the patients with candidiasis.
Among the sarcoidosis patients who were receiving or not receiving corticosteroid therapy, there were no significant differences in the D-and L-arabinitol concentrations or the Dand L-arabinitol/creatinine ratios. Moreover, there was no significant correlation by linear regression analysis between daily prednisone dosage and the D-or L-arabinitol concentrations or the D-or L-arabinitol/creatinine ratios.
Roentgenographic evidence of advanced pulmonary sarcoidosis was associated with higher serum D-arabinitol/ creatinine ratios but not with higher L-arabinitol/creatinine ratios. The serum D-arabinitol/creatinine ratios were higher in 18 patients with grade 4 chest roentgenograms (mean ± SD = 0.029 ± 0.011) than in 24 patients with grade 0 to 2 chest roentgenograms (0.016 + 0.0039, P = 0.0002). Whether these higher D-arabinitol/creatinine ratios were associated with past or current disease activity was examined by correlating the D-arabinitol/creatinine ratios with forced vital lung capacity and with two parameters of current disease activity (1, 2, 16 ). There was a significant negative correlation between the serum D-arabinitol/creatinine ratios and percentage of predicted forced vital lung capacity (r/ = -0.357, P = 0.0239, n = 40), but there were no significant correlations between the serum D-arabinitol/creatinine ratios and either the ratios of bronchoalveolar lymphocytes to total nucleated celis (i = -0.137, P = 0.412, n = 38) or the bronchoalveolar lymphocyte CD4/CD8 ratios (r = -0.200, P = 0.397, n = 20).
DISCUSSION
In 1984, Karam and co-workers reported serum arabinitol levels in 53 patients with sarcoidosis, 55 patients with Candicla species colonization or disease, 25 patients with other fungal infections, 25 patients with chronic obstructive pulmonary disease, 25 patients with end-stage renal disease who were receiving hemodialysis, and 25 healthy subjects (8) . The principal new finding was that 27 (51%) of the sarcoidosis patients had elevated arabinitol levels in serum (0.5 p.g/ml or more) compared with none of 25 healthy subjects. Those authors found no association between arabinitol levels in serum and either severity of disease as determined by chest roentgenograms or administration of corticosteroids, and they suggested that tissue injury associated with sarcoidosis may have resulted in increased arabinitol production by host tissues (8) .
A careful reading of that report reveals several potential methodologic problems. First, the GC analyses were performed with a low-resolution packed column, and the chromatographic conditions were such that the trimethylsilyl derivative of arabinitol eluted after only 3 min. The ade-quacy of the chromatographic separations cannot be assessed directly because representative chromatograms were not shown. However, we have analyzed trimethylsilylated human serum using many different packed and capillary GC columns, and we believe that arabinitol cannot be resolved from other serum components in 3 min with a packed OV-1 column (1.8 m by 2 mm) . Second, the minimum detection limit of the method used was too high (0.5 p.g of arabinitol per ml ofserum) to permit quantitative comparisons between groups; instead, any serum in which arabinitol was detectable was considered abnormal. Third, serum samples from 13 of 25 hemodialysis patients contained no detectable arabinitol; arabinitol should have been detectable in al of these samples because arabinitol accumulates in serum directly in proportion to creatinine (7, 19) . Fourth, none of 25 healthy subjects had detectable amounts of arabinitol in the urine, whereas several groups have shown that arabinitol is a normal constituent of human urine (3, 10, 11, 17, 19) . Lastly, arabinitol/creatinine ratios were not used to correct for the effects of renal function.
Because of these problems, we reexamined the issue of arabinitol levels in serum of sarcoidosis patients using a sensitive and accurate combined enzymatic and GC method.
The method used in this study clearly separates arabinitol from all other serum constituents, and it is sensitive enough (minimum detection limit, <0.08 1Lg/ml[211) to yield quantitative results in all sera and urines studied to date. In We alsofound no significant differences in the levels of Dor L-arabinitol in serum between the sarcoidosis patients who were receiving corticosteroids and those who were not.
This confirms the results reported by Gold et al. (7) , who found no differences in the serum arabinitol/creatinine ratios of steroid-treated and untreated cancer patients without candidiasis. In contrast, de Repentigny et al. reported markedly higher arabinitol concentrations and arabinitol/creatinine ratios in serum from uninfected rabbits given cortisone acetate than in saline controls (5) and in uninfected cancer patients receiving steroids than in those not receiving steroids (6) . We 
